Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • axial spondyloarthritis

    - PMLiVE

    UCB’s Fintepla shows positives results for Lennox-Gastaut syndrome

    The study demonstrated a sustained reduction in seizures for patients

    - PMLiVE

    Johnson & Johnson files FDA application for Tremfya in psoriatic arthritis

    Approximately 125 million people globally are living with some form of psoriasis

    - PMLiVE

    UCB shares promising results for fenfluramine in ultra-rare form of epilepsy

    CDKL5 deficiency disorder occurs in approximately one in 40,000 to 60,000 live births

    - PMLiVE

    GSK’s Blenrep combination recommended by NICE to treat multiple myeloma

    The decision means that eligible patients in England will be the first in the world to access the combination

    - PMLiVE

    UCB’s Bimzelx demonstrates lasting efficacy in phase 3 psoriatic arthritis trials

    Approximately 125 million people worldwide are affected by some form of psoriasis

    - PMLiVE

    Johnson & Johnson shares positive late-stage results for Tremfya in psoriatic arthritis

    The inflammatory condition affects approximately 30% of psoriasis patients

    - PMLiVE

    NICE recommends Gideon Richter’s Ryeqo as first daily pill for endometriosis

    Around 1,000 patients could benefit from the relugolix combination therapy every year

    - PMLiVE

    Amgen’s Blincyto recommended by NICE for new adult leukaemia indication

    Up to 50% of acute lymphoblastic leukaemia patients will relapse after initial treatment

    - PMLiVE

    AstraZeneca receives NICE recommendations for lung cancer drugs Tagrisso and Imfinzi

    More than 49,000 people are diagnosed with lung cancer in the UK each year

    - PMLiVE

    NICE recommends Santhera’s Duchenne muscular dystrophy drug Agamree

    Approximately 1,700 patients with the muscle-wasting disorder in England are expected to benefit from the decision

    - PMLiVE

    NICE recommends Immunocore’s Kimmtrak as first drug for aggressive eye cancer

    More than 100 patients are expected to be eligible for the treatment every year

    - PMLiVE

    UCB’s Bimzelx granted FDA approval to treat hidradenitis suppurativa in adults

    The inflammatory skin disease affects approximately one in every 100 people in the US

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links